KAT2B and cardiac hypertrophy: Furthermore, we blocked the TAK1-JNK/p38 signaling pathway with a TAK1 inhibitor (iTAK1), owing to which the effects of GCN5 overexpression were inhibited in both TAC- and PE-induced cardiac hypertrophy models.